Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPHASIS Study of eribulin monotherapy for advanced extramammary Paget's disease
jRCT2011220022Phase 2Recruiting
- Sponsor
- Hokkaido University Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in extramammary Paget disease (EMPD), sponsored by Hokkaido University Hospital. Primary endpoint: Overall response rate. Started May 2023; status: recruiting.
02
Drugs
eribulin
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCT2011220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220022.